Clinical Trials Logo

Filter by:
NCT ID: NCT01379729 Recruiting - Type 1 Diabetes Clinical Trials

Bet Cell Therapy in Diabetes Type 1

Start date: May 2011
Phase: Phase 2
Study type: Interventional

Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT. Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during hyperglycemic clamp at 180 mg/dl. The investigators hypothesize that functional beta-cell mass will be more than 20% compared to healthy controls. Secondary outcome measurements: Functional beta-cell mass at 2,12,18,24,36,48 and 60 months PT. The investigators will also compare at 2, 6,12, 24,36,48 and 60 months the changes against base-line (base-line = before first intraperitoneal transplantation): - metabolic control - safety parameters - episodes of hypoglycemia - islet cell autoantibodies, lymphocyte subsets, T-cell reactivity against auto- and alloantigens using pre-transplant measurements as base-line The investigators hypothesize that metabolic control and prevalence of hypoglycemia, will be significantly improved till PT month 12. Histopathology of a biopsy specimen of the human intraperitoneal beta cell implant, at time of the second implant. Comparison with composition of graft, identification of microenvironment of host origin and correlation with functional assessment will be performed.

NCT ID: NCT01356654 Recruiting - Stroke Clinical Trials

Transcranial Direct Current Stimulation in Stroke Rehabilitation

Start date: March 2010
Phase: N/A
Study type: Interventional

This study investigates if transcranial Direct Current Stimulation (tDCS) is effective in the recovery of postural control in stroke rehabilitation.

NCT ID: NCT01352923 Recruiting - Platelet Function Clinical Trials

Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

Start date: May 2011
Phase: N/A
Study type: Interventional

In this study PEAR1 polymorphisms effects will be analyze in blood platelets to determine how PEAR1 regulates platelet activation.

NCT ID: NCT01347216 Recruiting - Clinical trials for Pulmonary Arterial Hypertension (PAH)

COMPERA / COMPERA-KIDS

COMPERA
Start date: July 1, 2007
Phase:
Study type: Observational

In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in >50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH. Since July 2013, also children of any age can be documented (COMPERA-KIDS).

NCT ID: NCT01332240 Recruiting - Clinical trials for Stage III Lung Cancer

External ValidatIon Trial of ASTER Trial

EVITA
Start date: April 2011
Phase: N/A
Study type: Interventional

As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely spread in Belgium, the investigators aimed to determine the number of mediastinoscopies needed to detect one additional mediastinal lymph node invasion during routine clinical practice in the staging of potentially resectable clinical stage III non-small cell lung cancer.

NCT ID: NCT01331915 Recruiting - Melanoma Clinical Trials

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

THERAVAC
Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease. The primary objective is to analyze the safety of the inreasing doses of vaccine. The secondary objective is to document whether this vaccine can induce tumor regression in immunized patients.

NCT ID: NCT01331668 Recruiting - Kidney Failure Clinical Trials

BIOBANK Renal Transplantation University Hospitals Leuven

Start date: March 2004
Phase:
Study type: Observational

This study aims to maintain a prospective biobank of human samples obtained from donors and recipients of renal allografts, including biopsy tissue, peripheral blood samples and urine samples.

NCT ID: NCT01330849 Recruiting - Clinical trials for Attention-deficit/Hyperactivity Disorder

Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start date: December 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the efficacy of the ADHD-Toolkit (a toolkit for school behaviour modification in primary school children with ADHD-behaviours) in terms of general improvement in ADHD symptoms, specific targeted school-related problem behaviours, other disruptive behaviour disorder symptoms, teacher attitudes towards ADHD, teacher-child relationship and child self-esteem.

NCT ID: NCT01329835 Recruiting - Clinical trials for Obese Pregnant Women

Effect of Psycho-education on Gestational Weight Gain and Anxiety/Depression in Obese Pregnant Women

Start date: March 2008
Phase: N/A
Study type: Interventional

Prepregnancy obesity, defined as a body mass index (BMI) of 30kg/m² or more, shows a strong association with pregnancy and birth complications for both the mother and her child. Most consequently reported maternal risks include an increased risk for gestational diabetes, hypertension and pre-eclampsia, increased incidence of induction of labour, operative delivery, postpartum haemorrhage, anaesthetic risks as well as risk for infections and thromboembolic complications. Fetal risks include miscarriage, neural-tube defects, heart defects, macrosomia and stillbirth. Initiation and continuation of breastfeeding is more complicated in obese women than in normal weight women. Also in later life chronic diseases can put the mother and her baby's health at risk. The Institute Of Medicine (IOM) guidelines suggest a gestational weight gain (GWG) to be limited to 5 - 9 kg (11-19,8 lb) in obese women in order to minimize the synergetic negative health consequences of excessive weight gain for both the obese mother and her child. Preventing excessive weight gain during pregnancy and postpartum weight retention is also important in the prevention of overweight and obesity among women of reproductive age. Obese women in general have a poor diet quality and are more exposed to psychosocial factors like anxiety and feelings of depression than normal weight women. The aim of this project is to perform a randomized controlled trial (RCT) in order to evaluate the effects of life-style intervention (psycho-education by a midwife during 4 prenatal sessions) on pregnancy and birth outcomes. Main dependent variables are gestational weight gain and anxiety and depression. Obesity is a modifiable risk factor and optimizing an adequate gestational weight gain with attention to psycho-social factors, can reduce the need for adverse perinatal outcomes.

NCT ID: NCT01318785 Recruiting - Lymphedema Clinical Trials

Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications

BF09-PH-01
Start date: September 2011
Phase: Phase 2
Study type: Interventional

Examination of therapeutical effects of different types of armsleeves in treating lymphatic diseases after breast cancer surgery during maintenance phase 1. thesis: - all types should be equal regarding volume reduction 2. thesis: armsleeves manufactured with microfibre yarn are expected to be - better in wearing comfort and - better in handling features.